7th International Immunoglobulin Conference: Immunomodulation

Area of Science:

• Immunology
• Rheumatology
• Reproductive Medicine

Background:

• Immunomodulation involves modifying immune responses using various agents to treat autoimmune conditions.
• Rheumatoid arthritis (RA) affects 1% of the global population, with methotrexate as a first-line therapy and over 40 monoclonal antibodies under investigation.
• Autoimmune bullous diseases like pemphigus and pemphigoid involve autoantibodies targeting specific antigens, with IVIg showing efficacy as adjuvant therapy.

Discussion:

• The availability of diverse biological agents allows for tailored treatment strategies in RA when initial therapies fail.
• Intravenous immunoglobulin (IVIg) effectively reduces autoantibody levels and disease severity in autoimmune bullous diseases, often in conjunction with cytotoxic drugs.
• The precise mechanism of IVIg in secondary recurrent miscarriage (RM) remains unclear, though it correlates with a decrease in natural killer cell biomarkers.

Key Insights:

• Monoclonal antibodies represent a significant advancement in RA treatment, offering alternative mechanisms of action.
• IVIg demonstrates therapeutic potential in autoimmune bullous diseases and secondary RM, warranting further investigation.
• Optimizing IVIg dosage and understanding its immunomodulatory effects are crucial for its application in recurrent miscarriage.

Outlook:

• Continued research into monoclonal antibodies will expand treatment options for RA and potentially other autoimmune conditions.
• Further clinical trials are essential to establish definitive treatment protocols for IVIg in autoimmune bullous diseases and secondary RM.
• Elucidating the immunomodulatory pathways of IVIg could lead to novel therapeutic strategies for immune-mediated reproductive disorders.